Welcome to our dedicated page for Xencor SEC filings (Ticker: XNCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xencor, Inc. (XNCR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, Xencor uses its SEC filings to report material events, financial results and key corporate developments related to its XmAb® technology platform and pipeline.
Investors can review Form 8-K filings in which Xencor reports quarterly financial results, such as revenue from collaborations, milestones and royalties, research and development expenses, and cash and marketable securities balances. These filings often incorporate press releases that summarize progress in clinical programs like XmAb819, XmAb541, plamotamab, XmAb657, XmAb942 and XmAb412, as well as updates on partnered programs and royalty-bearing products.
Xencor’s SEC filings also cover corporate actions and governance changes, including board appointments and director compensation, and Regulation FD disclosures related to investor presentations and webcasts. For example, the company has filed 8-Ks to furnish presentation materials and press releases discussing initial Phase 1 results of XmAb819 and early data from XmAb541, along with associated clinical timelines.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points in each document, helping readers quickly understand the implications of new information. Users can monitor real-time updates from EDGAR, track items related to financial condition, material clinical data disclosures, and governance events, and use the structured view of XNCR filings to follow how Xencor’s antibody engineering business and pipeline are reflected in its regulatory reporting.